
Veterans may be up to 5 times more likely to have hepatitis C than the general population.

Veterans may be up to 5 times more likely to have hepatitis C than the general population.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Patients with hepatitis C virus achieve treatment success with specialists, primary care physicians, and nurse practitioners.

The lack of association of SVR with ribavirin dose reflects the wide variance in plasma levels between individuals with hepatitis C receiving the same weight-based dosage.

Heart transplant patients with hepatitis C often cannot not tolerate interferon-based regimens due to cardiac toxicity and other heart-related problems.

Drinking coffee may have more profound survival benefits for patients with HIV and hepatitis C than for the general population.

Researchers continue to focus on developing an 8-week treatment regimen for hepatitis C virus.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

A look at the top stories in pharmacy last week.

A look at the top stories in pharmacy last week.

Top news from across the healthcare landscape.

Top news from across the healthcare landscape.

Top news of the week from Specialty Pharmacy Times.

National brand spending and new patient rates for hepatitis C virus dropped last year.

The pharma giant will now focus on its PD-1 cancer immunotherapy Keytruda.

Ramping up programs for injection drug users is a key part in preventing transmission of hepatitis C.

Testing and treatment programs should focus on populations driving new cases of hepatitis C virus.

Top news of the day from across the health care landscape.

Recent studies suggested that hepatitis C antiviral drugs may increase the risk of hepatocellular carcinoma.

Top news of the day from across the healthcare landscape.

There are several key therapeutics areas of which to be aware.

Top news of the day from across the health care landscape.

This decision was made based on a review of available phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options available for patients with chronic HCV infection, including elbasvir and grazoprevir (Zepatier).